Core Insights - Rakovina Therapeutics is advancing next-generation cancer therapies through AI-powered drug discovery, highlighting its strategic objectives for H2 2025 amid a rapidly evolving global AI landscape [1][2]. Industry Overview - The biopharmaceutical industry is experiencing a transformative shift due to artificial intelligence, which is significantly impacting drug discovery, testing, and delivery processes [2]. - Recent collaborations, such as AstraZeneca's $5.3 billion agreement with CSPC Pharmaceutical Group, underscore the growing momentum in AI-driven drug development [2]. Company Highlights - Rakovina holds exclusive licenses to two AI discovery platforms, Deep Docking™ and Enki™, which can analyze billions of chemical structures at 100 times the speed of traditional methods [3]. - The Deep Docking™ platform was developed by Dr. Artem Cherkasov, who previously identified a compound that was licensed to Roche for $142 million, marking a significant achievement in life-sciences IP [4]. - The company operates an integrated discovery engine that combines in silico screening with biochemical and cellular validation through a collaboration with UBC [5]. H1 2025 Accomplishments - Rakovina presented two scientific posters at the AACR 2025 meeting, showcasing advancements in AI-derived DNA-damage response inhibitors [8]. - The kt-2000 program demonstrated improved metabolic stability and pharmacokinetic profiles, while the kt-5000 program unveiled potent ATR inhibitor candidates designed for CNS penetration [8]. - The company strengthened its financial position by closing an oversubscribed private placement and convertible debt financing of CAD 4.9 million [8]. - Rakovina began trading on the Frankfurt exchange and appointed new financial and scientific leaders to enhance governance and expertise [8]. Strategic Objectives for H2 2025 - The company plans to enter development collaborations for lead candidates in Q3 2025 and continue advancing preclinical development of its DNA Damage Response therapies [14]. - Rakovina aims to integrate AI and data science to enhance drug discovery capabilities and expand engagement with global institutional investors and strategic partners [14]. - The company seeks to secure non-dilutive funding through government initiatives and strategic alliances to support expanded drug development activities [14].

Core Points - Rakovina Therapeutics Inc. will implement a share consolidation effective June 24, 2025, at a ratio of one post-consolidation share for every ten pre-consolidation shares [1][2] - The new common shares will trade on the TSX Venture Exchange under the existing symbol "RKV" starting June 24, 2025, with a new CUSIP number 75103L309 and ISIN number CA75103L3092 [2] - The company will have approximately 21,148,038 common shares issued and outstanding post-consolidation [2] Shareholder Instructions - The company's transfer agent, Odyssey Trust Company, will send a letter of transmittal to registered shareholders for exchanging pre-consolidation share certificates for post-consolidation certificates [4] - Fractional shares resulting from the consolidation will be rounded up or down based on the specified criteria [2] Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using unique technologies for targeting the DNA-damage response, powered by Artificial Intelligence [6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that members of its executive team will attend the 2025 BIO International Convention, taking place June 16th – 19th in Boston, Massachusetts. Rakovina Therapeutics’ management will participate in one-on-one partnering ...

Core Viewpoint - Rakovina Therapeutics Inc. has successfully closed a non-brokered private placement, raising gross proceeds of $4,905,150 to support its innovative cancer therapies and AI-driven drug discovery initiatives [1][7]. Private Placement Details - The private placement includes $3,555,150 from equity units (Units) and $1,350,000 from convertible debenture units (Debenture Units) [1][2]. - Each Unit is priced at $0.05 and consists of one common share and one warrant, allowing the purchase of an additional common share at $0.10 for 24 months [2]. - Each Debenture Unit comprises a $50,000 unsecured convertible debenture and 100,000 warrants, with the warrants allowing the purchase of a common share at $0.15 for 24 months [3]. Financial Terms - The debentures will accrue interest at 12% per annum and are repayable in 36 months, with an option for conversion into common shares at $0.10 [3]. - The company paid cash finder's fees totaling $60,035.50 and issued 1,200,710 finder's warrants, each allowing the purchase of a common share at $0.10 for 24 months [4]. Insider Participation - Insiders subscribed for 14,700,000 Units, generating $735,000 in gross proceeds, which is considered a related party transaction [5]. - The company is relying on exemptions from formal valuation and minority shareholder approval requirements under MI 61-101 [5]. Share Consolidation - A 10-for-1 share consolidation is planned following the private placement, with all amounts presented on a pre-consolidation basis [6]. Use of Proceeds - Proceeds from the financing will support the integration of AI-driven drug discovery tools and enhance visibility among institutional investors in U.S. and global capital markets [7][8]. Investor Relations and Marketing - Rakovina has engaged Fairfax Partners as its Investor Relations partner and Machai Capital for corporate communication services [9]. - Fairfax will implement a three-month IR program with a budget of $250,000, focusing on online marketing and social media [10]. - Machai Capital will enhance marketing campaigns with a budget of $250,000, utilizing various digital marketing strategies [11]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI technologies for targeting DNA-damage response [13]. - The company aims to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners [14].

Core Viewpoint - Rakovina Therapeutics Inc. reported its Q1 2025 financial results and provided updates on corporate developments, highlighting advancements in AI-powered cancer therapies and strategic financial maneuvers to preserve cash resources [1][5]. Financial Highlights - Cash and cash equivalents stood at $75.8 million, while working capital was negative at $(1.45) million [4]. - The company reported a net loss of $2.18 million, aligning with expectations, with R&D expenses totaling $855,594, reflecting ongoing development of AI-driven drug candidates [5][6]. - General and administrative expenses were $1.22 million, which included costs related to investor relations and exchange fees [5]. - Net cash used in operating activities for the quarter was $1.24 million [5]. Recent Corporate Developments - On May 28, 2025, certain debenture holders opted for common shares instead of cash for interest payments, aiding in cash preservation [5]. - A strategic private placement and convertible debt financing of approximately $4 million was announced on May 15, 2025, with a lead order of $3 million from a strategic investor [5]. - The company plans a 10-for-1 share consolidation, expecting to have around 20 million shares outstanding post-offering [5]. - Dr. David Kideckel was appointed as Chief Financial Officer, pending TSX Venture Exchange approval [5]. - Pre-clinical data for the kt-2000 and kt-5000 programs were presented at the AACR annual meeting, indicating potential alignment with target product profiles [5]. - The company received its first batch of AI-generated ATR inhibitor compounds in collaboration with Variational AI on March 12, 2025 [5]. Share Performance and Market Presence - The company’s common shares were listed on the Frankfurt Stock Exchange under the ticker symbol "7J0" on January 30, 2025 [5]. - The weighted average shares outstanding increased to 140,772,575 from 70,084,925 year-over-year [6].

$3 Million Lead Order from Strategic Investors Supports Bold TransformationVANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announces a strategic financing of approximately $4 million (the “Offering”) consisting of concurrent private placements of (i) convertible debenture units (“De ...

Core Insights - Rakovina Therapeutics Inc. has appointed Dr. David M. Kideckel as Chief Financial Officer, pending approval from the TSX Venture Exchange [1] - Dr. Kideckel has nearly two decades of experience in life sciences and capital markets, with a focus on scaling operations for healthcare companies [2] - The company is advancing innovative cancer therapies through AI-powered drug discovery, utilizing proprietary platforms [6][7] Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments, particularly through DNA-damage response inhibitors [6][7] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [7] Leadership Transition - Dr. Kideckel's appointment comes during a critical growth phase for the company, as stated by Executive Chairman Jeffrey Bacha [5] - David Hyman, the outgoing CFO, will remain in a consulting role after stepping down, having established robust financial systems for the company [5] Dr. Kideckel's Background - Dr. Kideckel has held leadership roles at ATB Capital Markets, Johnson & Johnson, and Alexion Pharmaceuticals, contributing to drug development and commercialization [3] - He holds a Ph.D. in Neuroscience and Statistics and an MBA from the University of Toronto [4]

Core Insights - Rakovina Therapeutics Inc. reported its financial results for Q4 and the fiscal year ending December 31, 2024, highlighting advancements in AI-powered drug discovery for cancer therapies [1][2] Financial Performance - The company had a net loss of $1,483,988 for Q4 2024 and $4,072,618 for the entire year [4] - Research and development expenses were $744,533 for Q4 and $2,341,600 for the year, while general and administrative expenses were $650,268 for Q4 and $1,446,451 for the year [4][5] - As of December 31, 2024, the company had cash and cash equivalents of $1,312,743 and total assets of $6,240,920, with total liabilities of $1,942,005 [5] Corporate Developments - The company intends to appoint Yevgeniy Meshcherekov and David Kideckel to its board of directors, pending TSX Venture Exchange approval [2] - Michael Liggett has retired from the board, and Meshcherekov is set to replace him as chair of the audit committee [2] - Rakovina presented pre-clinical data for its kt-2000 and kt-5000 programs at the AACR annual meeting, indicating potential alignment with target product profiles [2] Research and Development - The company received its first synthesized batch of AI-generated ATR inhibitor compounds in collaboration with Variational AI [2] - Rakovina has established a pipeline of DNA-damage response inhibitors and aims to advance drug candidates into human clinical trials [6][7] - Collaborations with UBC and Pharma Inventor Inc. have been expanded to support AI drug discovery initiatives [8]

Core Viewpoint - Rakovina Therapeutics Inc. has appointed Mr. Yevgeniy Meshcherekov and Dr. David Kideckel to its board of directors, enhancing its governance and financial expertise as it advances its AI-driven cancer therapies [1][6][7]. Group 1: Appointments and Governance - Mr. Yevgeniy Meshcherekov brings over 20 years of experience in financial management across various industries, including fintech and blockchain [2][3]. - Dr. David Kideckel has nearly 20 years of experience in the Life Sciences sector, having held senior roles in healthcare and biotechnology, including at Johnson & Johnson and Alexion Pharmaceuticals [5][6]. - The appointments are aimed at strengthening Rakovina's financial and capital markets infrastructure in preparation for upcoming drug development milestones [6][7]. Group 2: Leadership Changes - Michael Liggett has retired from the board, having significantly contributed to the company's strategic direction and growth in the healthcare sector [8][9]. - The transition in leadership is expected to drive fiscal discipline and operational scale as the company continues to develop its oncology programs [7]. Group 3: Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments using AI technologies, specifically targeting DNA-damage response through its proprietary platforms [9][10]. - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [10].

The second presentation showcased progress from Rakovina's ATR-specific inhibitor program, developed in partnership with Variational AI. Researchers identified a focused set of lead candidates predicted to be highly potent and selective against ATR, a key DNA damage response target. These candidates are also designed with the potential to cross the blood-brain barrier, an important feature for addressing cancers affecting the CNS. The top candidates are currently being synthesized for laboratory validation. ...